BioLineRx (BLRX) Depreciation & Amortization (CF) (2014 - 2025)
BioLineRx (BLRX) recorded quarterly Depreciation & Amortization (CF) of $63000.0 in Q4 2025, down 47.06% quarter-over-quarter from $119000.0 in Q3 2025, and down 96.6% on a YoY basis from $1.9 million in Q4 2024.
BioLineRx (BLRX) Depreciation & Amortization (CF) (2014 - 2025) Analysis & Trends
BioLineRx's Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $63000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 96.6% year-over-year to $63000.0; the TTM figure through Dec 2025 stood at $523000.0 (down 87.13% YoY), while the FY2025 annual figure was $523000.0, down 87.13% from the prior year.
- Depreciation & Amortization (CF) was $63000.0 for Q4 2025 at BioLineRx, down from $119000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.9 million in Q4 2024 to a low of $63000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $366450.0 across 5 years, with a median of $181000.0 in 2021.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) soared 280.09% in 2024, then plunged 96.6% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $174000.0 in 2021, then advanced by 7.47% to $187000.0 in 2022, then surged by 277.54% to $706000.0 in 2023, then surged by 162.32% to $1.9 million in 2024, then slumped by 96.6% to $63000.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $63000.0 (Q4 2025), $119000.0 (Q3 2025), and $176000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | 63,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 63,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 176,000.00 |
| Jun 30, 2025 | 176,000.00 |
| Mar 31, 2025 | 165,000.00 |
| Mar 31, 2025 | 165,000.00 |
| Dec 31, 2024 | 1.85 Mn |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 840,000.00 |
| Sep 30, 2024 | 840,000.00 |
| Jun 30, 2024 | 476,000.00 |
| Jun 30, 2024 | 476,000.00 |
| Mar 31, 2024 | 897,000.00 |
| Mar 31, 2024 | 897,000.00 |
| Dec 31, 2023 | 706,000.00 |
| Dec 31, 2023 | 706,000.00 |
| Sep 30, 2023 | 221,000.00 |
| Sep 30, 2023 | 221,000.00 |